Avacta Expands Following Aptuscan Acquisition
News Jul 09, 2012
Avacta Group has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space.
The move, which follows the recent acquisition of affinity reagents specialist Aptuscan, brings together the entire Avacta Group on the same site.
The new facilities, which include purpose built laboratories, are at Avacta’s existing Thorp Arch Estate premises in Wetherby, UK, and have been taken on to accommodate the Company’s current rapid expansion.
Alastair Smith, Chief Executive of Avacta, commented: “Our core businesses are seeing strong growth, and recent funding, together with the acquisition of Aptuscan, will ensure we are able to accelerate our existing product development pipeline. Thorp Arch Estate is an ideal location for biotechnology enterprises, with excellent transport connections, and we are enthusiastic about plans to create a wider science park facility here.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE